HKEX's new Hang Seng Biotech Index Futures to debut next month

Core Viewpoint - Hong Kong Exchanges and Clearing (HKEX) is set to launch the Hang Seng Biotech Index Futures on November 28, aimed at providing a risk management tool for investors interested in the rapidly growing biopharmaceutical sector in mainland China [1][3]. Group 1: Product Details - The Hang Seng Biotech Index Futures will be based on the Hang Seng Biotech Index, tracking the performance of the 30 largest Hong Kong-listed Chinese pharmaceutical and medical device companies [2]. - The futures will trade under the code HBI, with a contract multiplier of HK$50 (approximately US$6.40) per index point [5]. Group 2: Market Impact - The introduction of this futures product is part of HKEX's strategy to enhance Hong Kong's status as Asia's leading derivatives trading and risk management center, catering to the evolving needs of global investors [3][4]. - The new futures contracts are expected to increase market liquidity by attracting more institutional investors to participate in equity trading [6]. Group 3: Regulatory Aspects - The Securities and Futures Commission will waive the transaction levy for the first six months of trading for the new contracts, with margin rates to be announced later [6].